Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
November 30, 2023 16:48 ET
|
Biora Therapeutics, Inc.
BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 13, 2023 16:05 ET
|
Biora Therapeutics, Inc.
NaviCap™ platform advancing toward initiation of phase 1 clinical trial by year end; Pharma collaborations accelerate for the BioJet™ platform
Biora Therapeutics to Report Third Quarter 2023 Financial Results and Provide Corporate Update
November 06, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Biora will report financial results and provide a corporate update for the third quarter on on Monday, November 13, 2023, at 4:30 PM EST / 1:30 PM PST
Biora Therapeutics Submits Updated IND Application for BT-600
October 30, 2023 16:05 ET
|
Biora Therapeutics, Inc.
Update includes supplemental information and provides additional time to complete regulatory review; company expects to remain on track with Ph1 timeline.
Biora Therapeutics to Submit Updated IND Application for BT-600
October 23, 2023 17:30 ET
|
Biora Therapeutics, Inc.
Update to include supplemental information and allow additional time for regulatory review. Biora anticipates remaining on track with ph1 trial timeline.
Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes
October 05, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies
Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program
September 25, 2023 08:00 ET
|
Biora Therapeutics, Inc.
BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis IND application is supported by robust...
Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure
September 19, 2023 08:00 ET
|
Biora Therapeutics, Inc.
Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023 ...
Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 11, 2023 08:01 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming...
Biora Therapeutics Progresses its BioJet™ Systemic Oral Delivery Platform
September 05, 2023 08:00 ET
|
Biora Therapeutics, Inc.
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced achievement of its device...